Search results
7 Penny Stocks With 10x Potential This Year
InvestorPlace via Yahoo Finance· 2 years agoPenny stocks can multiply in value quickly, these picks have 10x potential this year. Regulus Therapeutics (RGLS): Represents traditional pharma...
Regulus Therapeutics (RGLS): An Attractive Valuation or a Potential Value Trap?
GuruFocus.com via Yahoo Finance· 8 months agoValue-focused investors are always on the hunt for stocks that are priced below their intrinsic...
Regulus (RGLS) Up as FDA Accepts IND for Kidney Disease Drug
Zacks via Yahoo Finance· 2 years agoThe FDA accepts Regulus' (RGLS) IND application for RGLS8429 to treat autosomal dominant polycystic...
Regulus (RGLS) Up on Top-Line Data from Kidney Disease Study
Zacks via Yahoo Finance· 2 years agoRegulus Therapeutics (RGLS) reports positive top-line data from a phase I single-dose ascending...
Biotech Stock Roundup: AMLX, ACAD Down on Study Data, MRNA, RGLS Gain on Updates & More
Zacks via Yahoo Finance· 1 month agoIt was a busy week for the biotech sector with lots of study data readouts and regulatory approvals....
Regulus Therapeutics Inc's Uncertain Future: Understanding the Barriers to Outperformance
GuruFocus.com via Yahoo Finance· 8 months agoLong-established in the Biotechnology industry, Regulus Therapeutics Inc (NASDAQ:RGLS) has enjoyed a...
13 Best Biotech Penny Stocks To Buy Now
Insider Monkey via Yahoo Finance· 1 year agoIn this article, we will be taking a look at the 13 best biotech penny stocks to buy now. To skip our detailed analysis of these stocks, you can go...
Regulus: Q2 Earnings Snapshot
AP Finance via Yahoo Finance· 9 months agoSAN DIEGO (AP) — SAN DIEGO (AP) — Regulus Therapeutics Inc. (RGLS) on Tuesday reported a loss of $7 million in its second quarter. On a per-share basis, the San Diego-based company said it had ...
Regulus Shares Surge After Early-Stage RGLS8429 Data In Rare Kidney Disease
Benzinga via Yahoo Finance· 2 years agoBiopharmaceutical company Regulus Therapeutics Inc (NASDAQ: RGLS) shares jumped after topline safety...
Sanofi Opts To Terminate Rare Disease Program With Regulus Therapeutics
Benzinga via Yahoo Finance· 1 year agoSanofi SA (NASDAQ: SNY) elected to terminate its second amended and restated collaboration and...
